DANONE (BSN.DE) Stock Fundamental Analysis
FRA:BSN - FR0000120644 - Common Stock
73.88 EUR
-0.26 (-0.35%)
BSN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 59 industry peers in the Food Products industry. BSN has an average financial health and profitability rating. BSN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BSN was profitable.
BSN had a positive operating cash flow in the past year.
BSN had positive earnings in each of the past 5 years.
BSN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of BSN (4.20%) is comparable to the rest of the industry.
The Return On Equity of BSN (11.59%) is better than 66.10% of its industry peers.
The Return On Invested Capital of BSN (6.83%) is better than 64.41% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BSN is in line with the industry average of 6.58%.
The last Return On Invested Capital (6.83%) for BSN is above the 3 year average (6.38%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROIC | 6.83% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
BSN's Profit Margin of 6.72% is fine compared to the rest of the industry. BSN outperforms 69.49% of its industry peers.
In the last couple of years the Profit Margin of BSN has remained more or less at the same level.
With a decent Operating Margin value of 13.25%, BSN is doing good in the industry, outperforming 74.58% of the companies in the same industry.
In the last couple of years the Operating Margin of BSN has declined.
BSN's Gross Margin of 50.47% is fine compared to the rest of the industry. BSN outperforms 72.88% of its industry peers.
BSN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
BSN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, BSN has more shares outstanding
BSN has less shares outstanding than it did 5 years ago.
The debt/assets ratio for BSN has been reduced compared to a year ago.
2.2 Solvency
BSN has an Altman-Z score of 2.50. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of BSN (2.50) is better than 62.71% of its industry peers.
BSN has a debt to FCF ratio of 5.07. This is a neutral value as BSN would need 5.07 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.07, BSN is in the better half of the industry, outperforming 61.02% of the companies in the same industry.
BSN has a Debt/Equity ratio of 0.83. This is a neutral value indicating BSN is somewhat dependend on debt financing.
The Debt to Equity ratio of BSN (0.83) is worse than 69.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 2.5 |
ROIC/WACC1.09
WACC6.24%
2.3 Liquidity
A Current Ratio of 0.95 indicates that BSN may have some problems paying its short term obligations.
BSN's Current ratio of 0.95 is on the low side compared to the rest of the industry. BSN is outperformed by 76.27% of its industry peers.
A Quick Ratio of 0.78 indicates that BSN may have some problems paying its short term obligations.
BSN has a Quick ratio of 0.78. This is comparable to the rest of the industry: BSN outperforms 42.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.47% over the past year.
Measured over the past years, BSN shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.17% on average per year.
Looking at the last year, BSN shows a small growth in Revenue. The Revenue has grown by 0.54% in the last year.
The Revenue has been growing slightly by 1.60% on average over the past years.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
3.2 Future
BSN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.52% yearly.
The Revenue is expected to grow by 3.01% on average over the next years.
EPS Next Y7.96%
EPS Next 2Y7.64%
EPS Next 3Y7.59%
EPS Next 5Y5.52%
Revenue Next Year0.8%
Revenue Next 2Y1.86%
Revenue Next 3Y2.57%
Revenue Next 5Y3.01%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 19.75, the valuation of BSN can be described as rather expensive.
BSN's Price/Earnings is on the same level as the industry average.
The average S&P500 Price/Earnings ratio is at 26.76. BSN is valued slightly cheaper when compared to this.
BSN is valuated rather expensively with a Price/Forward Earnings ratio of 17.57.
BSN's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. BSN is more expensive than 62.71% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BSN to the average of the S&P500 Index (34.91), we can say BSN is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.75 | ||
| Fwd PE | 17.57 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BSN is on the same level as its industry peers.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BSN is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.55 | ||
| EV/EBITDA | 10.62 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BSN does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of BSN may justify a higher PE ratio.
PEG (NY)2.48
PEG (5Y)N/A
EPS Next 2Y7.64%
EPS Next 3Y7.59%
5. Dividend
5.1 Amount
BSN has a Yearly Dividend Yield of 3.00%.
BSN's Dividend Yield is a higher than the industry average which is at 3.36.
Compared to an average S&P500 Dividend Yield of 2.36, BSN pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
74.99% of the earnings are spent on dividend by BSN. This is not a sustainable payout ratio.
BSN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP74.99%
EPS Next 2Y7.64%
EPS Next 3Y7.59%
FRA:BSN (8/21/2025, 7:00:00 PM)
73.88
-0.26 (-0.35%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners48.65%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap50.34B
Analysts72.26
Price Target77.23 (4.53%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.43%
PT rev (3m)2.84%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.94%
Revenue NY rev (3m)-0.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.75 | ||
| Fwd PE | 17.57 | ||
| P/S | 1.84 | ||
| P/FCF | 17.55 | ||
| P/OCF | 13.09 | ||
| P/B | 3.17 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.62 |
EPS(TTM)3.74
EY5.06%
EPS(NY)4.21
Fwd EY5.69%
FCF(TTM)4.21
FCFY5.7%
OCF(TTM)5.64
OCFY7.64%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.48
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROCE | 12.02% | ||
| ROIC | 6.83% | ||
| ROICexc | 8.36% | ||
| ROICexgc | 50.58% | ||
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% | ||
| FCFM | 10.49% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexcg growth 3Y19.7%
ROICexcg growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 77.72% | ||
| Cap/Sales | 3.57% | ||
| Interest Coverage | 23.53 | ||
| Cash Conversion | 78.8% | ||
| Profit Quality | 156.01% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | 2.5 |
F-Score8
WACC6.24%
ROIC/WACC1.09
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y7.96%
EPS Next 2Y7.64%
EPS Next 3Y7.59%
EPS Next 5Y5.52%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.8%
Revenue Next 2Y1.86%
Revenue Next 3Y2.57%
Revenue Next 5Y3.01%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.65%
EBIT Next 3Y14.25%
EBIT Next 5Y9.87%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%